In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed BOSTON and...
Dasa Expands Its Capabilities with SOPHiA GENETICS
read more
Tel Aviv Sourasky Medical Center Chooses SOPHiA DDM™ HRD Solution of SOPHiA GENETICS
SOPHiA DDM™ HRD Solution will help empower clinical researchers to advance cancer research ...
Demystifying machine learning in healthcare: a layman’s guide to understanding the technology
This guide deciphers the jargon associated with machine learning in healthcare and explains why artificial intelligence is invaluable to revolutionize the capabilities of HCPs in improving patient care.
Celebrating 1 Year of SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution!
This week is marking one year from the official launch of the SOPHiA DDM TM Homologous Recombination Deficiency (HRD) Solution, accelerating and empowering our customers’ clinical cancer research decisions with cost-effective, accurate and fast in-house results.
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
The New Assay Will Screen Patients for Clinical Trials and Help Increase Data Analysis for...
Article Spotlight: NGS for investigating cardiac disease
Hospices Civils de Lyon in France share their insights from 5 years of experience using NGS for the molecular diagnosis of inherited cardiac diseases.
SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
Collaboration provides a solution for a more in-depth analysis of cancer biomarkers BOSTON and...
Hospitals in Ontario, Canada, were able to detect complex variants with their customized SOPHiA DDM™️ Community Comprehensive Hereditary Cancer Solution
SOPHiA DDM™️ successfully identified variants in the PMS2 pseudogene, low-level mosaicism, and processed pseudogenes.
SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
Fourth Quarter Revenue Growth Accelerates; Operating Losses Notably Moderate BOSTON &...
University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers
BOSTON and LAUSANNE, Switzerland, March 6, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...
SOPHiA GENETICS Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
Pioneer in decentralized digital health data analytics joins the ranks of
OpenAI, Disney, Tiffany & Co., and more
SOPHiA GENETICS and QIAGEN forge partnership to combine strengths in next-generation sequencing
BOSTON and LAUSANNE, Switzerland, March 1, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...